Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...
New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding ...
The COPD Action Alliance today released a new white paper, COPD in America and the Road to Better Care, outlining the urgent need for federal policymakers to recognize chronic obstructive pulmonary ...
Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor ...
When breathing becomes a daily battle, even the simplest acts can feel exhausting. Now, a new study has found the key to ...
Experts now urge healthcare providers and policymakers to consider more eco-friendly options in managing asthma and COPD ...
Researchers may have found a safe and effective treatment for chronic obstructive pulmonary disease (COPD) and interstitial ...
Expedition Therapeutics has closed a $165 million Series A financing round to support development of its lead candidate, EXPD ...
The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...
TipRanks on MSN
Sanofi’s Promising COPD Study: Lunsekimig’s Potential Impact
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...
For the first time, researchers have shown that tackling obstructive sleep apnea’s two root causes at once, using both oxygen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback